The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multi-center, randomized, double-blind phase II study comparing temozolomide (TMZ) plus either veliparib (ABT-888), a PARP inhibitor, or placebo as 2nd or 3rd-line therapy for patients (Pts) with relapsed small cell lung cancers (SCLCs).
 
Maria Catherine Pietanza
Honoraria - Abbvie; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech; Novartis
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech; Novartis
Speakers' Bureau - PER; Quintiles
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst); OncoMed (Inst); Stem CentRx (Inst)
 
Lee M. Krug
Employment - Bristol-Myers Squibb
 
Saiama Naheed Waqar
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Lilly (Inst); Newlink Genetics (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Spectrum Pharmaceuticals (Inst); Synermore biologics (Inst); Vertex (Inst); Xcovery (Inst)
 
Afshin Dowlati
Consulting or Advisory Role - Boehringer Ingelheim; Seagen
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Lilly/ImClone (Inst); MedImmune (Inst); OncoMed (Inst)
 
Christine L. Hann
No Relationships to Disclose
 
Alberto Chiappori
No Relationships to Disclose
 
Taofeek Kunle Owonikoko
Consulting or Advisory Role - Bayer; Celgene; Genentech/Roche; Novartis
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Celgene (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Genetic predictor of chemotherapy sensitivity (Inst)
 
Kaitlin Woo
No Relationships to Disclose
 
Yevgeniya Bensman
No Relationships to Disclose
 
Brenda Hurtado
No Relationships to Disclose
 
Junya Fujimoto
No Relationships to Disclose
 
Ignacio Ivan Wistuba
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Clovis Oncology; GE Healthcare; Genecentric; Genentech/Roche; GlaxoSmithKline; Lilly; Lilly
Speakers' Bureau - Boehringer Ingelheim; Medscape; Pfizer
Research Funding - Bayer; Genentech; Jounce Therapeutics; Merck; Myriad Genetics; OncoPlex Diagnostics
 
William D. Travis
No Relationships to Disclose
 
Alice P. Chen
No Relationships to Disclose
 
John Heymach
No Relationships to Disclose
 
Mark G. Kris
Consulting or Advisory Role - ARIAD; Array BioPharma; AstraZeneca; Clovis Oncology; Daiichi Sankyo; Genentech/Roche; Pfizer; Threshold Pharmaceuticals
Research Funding - Pfizer (Inst); Puma Biotechnology (Inst)
 
Martin Fleisher
No Relationships to Disclose
 
Charles M. Rudin
Consulting or Advisory Role - Abbvie; AVEO; Boehringer Ingelheim; Celgene; GlaxoSmithKline; Merck; Novartis
Research Funding - Biomarin
 
Lauren Averett Byers
Consulting or Advisory Role - Abbvie; AstraZeneca; Biomarin; Medivation
Research Funding - Takeda